Table 2.
Palliative first-line therapy
| N | % | |
|---|---|---|
| 1st CTX received | ||
| Yes | 48 | 94.1 |
| No (BSC) | 3 | 5.9 |
| Lines of therapy | ||
| 0 | 3 | 5.9 |
| 1 | 15 | 29.4 |
| 2 | 10 | 19.6 |
| 3 | 16 | 31.4 |
| > 3 | 4 | 7.8 |
| Median | 2 (range 0–5) | |
| Triplet CTX (FOLFOXIRI) | ||
| Yes | 12 | 23.5 |
| No | 38 | 74.5 |
| Unknown | 1 | 2.0 |
| First-line monoclonal antibody | ||
| Bevacizumab | 21 | 41.2 |
| EGFR (Panitumumab/Cetuximab) | 10 | 19.6 |
| None | 19 | 37.3 |
| Unknown | 1 | 2.0 |
| First-line chemotherapy backbone | ||
| Oxaliplatin-based (FOLFOX/CAPOX) | 19 | 37.3 |
| Irinotecan-based (FOLFIRI, Irinotecan) | 10 | 19.6 |
| FOLFOXIRI | 12 | 23.5 |
| Fluoropyrimidin mono | 3 | 5.9 |
| Other | 2 | 3.9 |
| Encorafenib | 1 | 2.0 |
| BSC | 3 | 5.9 |
| n.d. | 1 | 2.0 |